Quoin Pharmaceuticals, Ltd.
QRX003
Netherton Syndrome
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on QRX003 for Netherton Syndrome is in focus around Date TBD.
Primary source
· SEC 8-K
verified 15h ago
“On February 3, 2026, the U.S. Rare Pediatric Disease Priority Review Voucher (PRV) program was extended by Congress through September 30, 2029 as part of the Give Kids a Chance Reauthorization Act.”